Roivant Sciences (ROIV) Interest Coverage Ratio Growth (1y) (2021 - 2025)
Roivant Sciences (ROIV) Interest Coverage Ratio Growth (1y) (2021 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,831.58 Bn | 66,831.30 Bn | - | -60.44% |
| 2 | Nanobiotix | 1,916.61 Bn | 1,916.55 Bn | - | - |
| 3 | Akari Therapeutics | 976.78 Bn | 976.78 Bn | - | -347.04% |
| 4 | BeOne Medicines | 471.48 Bn | 466.69 Bn | 1.35 Bn | 787.12% |
| 5 | Vertex Pharmaceuticals | 121.78 Bn | 114.53 Bn | 2.59 Bn | 53.59% |
| 6 | Regeneron Pharmaceuticals | 69.87 Bn | 61.12 Bn | 3.31 Bn | -32.04% |
| 7 | Belite Bio | 63.06 Bn | 63.06 Bn | - | - |
| 8 | Argenx Se | 55.78 Bn | 50.60 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.54 Bn | 34.53 Bn | 959.66 Mn | 1,378.45% |
| 10 | Roivant Sciences | 24.18 Bn | 24.18 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -156,050.86% |
| Jun 30, 2025 | -123,191.45% |
| Dec 31, 2024 | -103.42% |
| Sep 30, 2024 | 87.08% |
| Jun 30, 2024 | 95.66% |
| Dec 31, 2023 | 482.76% |
| Sep 30, 2023 | 7.26% |
| Jun 30, 2023 | -21.55% |
| Dec 31, 2022 | 75.10% |
| Sep 30, 2022 | 51.70% |
| Jun 30, 2022 | 61.26% |
| Dec 31, 2021 | 44.55% |
| Sep 30, 2021 | 80.06% |
| Jun 30, 2021 | 57.54% |